Contrasting CytomX Therapeutics (CTMX) and Its Competitors

CytomX Therapeutics (NASDAQ:CTMX) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare CytomX Therapeutics to related companies based on the strength of its analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Risk and Volatility

CytomX Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500. Comparatively, CytomX Therapeutics’ peers have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.

Insider & Institutional Ownership

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares CytomX Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
CytomX Therapeutics Competitors	-9,046.59%	-199.78%	-30.61%

Earnings & Valuation

This table compares CytomX Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CytomX Therapeutics	$76.20 million	-$17.37 million	-4.38
CytomX Therapeutics Competitors	$691.14 million	$10.43 million	-15.00

CytomX Therapeutics’ peers have higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and price targets for CytomX Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1	1	9	1	2.83
CytomX Therapeutics Competitors	9801	15091	45424	1579	2.54

CytomX Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 447.95%. As a group, “Biotechnology” companies have a potential upside of 100.41%. Given CytomX Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe CytomX Therapeutics is more favorable than its peers.

Summary

CytomX Therapeutics beats its peers on 9 of the 12 factors compared.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.